Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00219024 · ClinicalTrials.gov registry record · Phase 3

Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.

A Phase 3 study of Hypertension, sponsored by Novartis.

Completed
Registry status
Phase 3
Development phase
2,775
Enrollment target
2
Study locations

NCT00219024: Completed Phase 3 study of Hypertension, sponsored by Novartis.

NCT00219024 is a Phase 3 study of Hypertension that has completed, run by Novartis. The registered enrollment target is 2,775 participants, below the 3,501-participant average among 470 other Hypertension trials with a reported enrollment target (21% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00219024, a Phase 3 study of Hypertension, has completed, sponsored by Novartis.

COMPLETED
Registry status
Phase 3
Development phase
2,775 participants
Enrollment target
2
Study locations

Study Summary

To demonstrate the efficacy and safety of aliskiren given to patients with essential hypertension, at doses of 75 mg, 150 mg and 300 mg alone, and in combination with hydrochlorothiazide (HCTZ)

Conditions Studied

Hypertension

Interventions

  • DRUG aliskiren

Study Locations (2)

New Jersey

  • Novartis Pharmaceuticals - East Hanover

Other

  • - Investigative Centers

Trial Details

FieldValue
Enrollment Target 2,775 participants
Start Date 2004-08
Est. Completion 2005-06
Phase Phase 3
Novartis

265 total trials

What the finished NCT00219024 record still lists

NCT00219024 is an interventional study that assigns participants to a tested intervention. Its 2,775 participants enrollment target places it among the larger protocols in the corpus, below the 3,501-participant average among 470 other Hypertension trials with a reported enrollment target (21% lower).

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which aliskiren is the first listed.

NCT00219024 reports a single indexed study location in New Jersey, Other.

Frequently Asked Questions

What is clinical trial NCT00219024 about?

NCT00219024 is a clinical study titled "Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.". To demonstrate the efficacy and safety of aliskiren given to patients with essential hypertension, at doses of 75 mg, 150 mg and 300 mg alone, and in combination with hydrochlorothiazide (HCTZ)

What is the current status of trial NCT00219024?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,775 participants. The study started on 2004-08. Estimated completion is 2005-06.

What conditions does trial NCT00219024 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT00219024?

The interventions under investigation include: aliskiren (DRUG).

Who is sponsoring clinical trial NCT00219024?

This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00219024 being conducted?

This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00219024's enrollment target sits among peer trials

2,775 36th of 470 higher than 435 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05443737 · 2,800 participants · Phase 3

    Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients

  • NCT05899439 · 2,800 participants

    Immune Function and the Progression to T1D

  • NCT06089109 · 2,800 participants · NA

    Creating VIP Corps to Reduce Maternal Deaths

  • NCT06345339 · 2,800 participants · Phase 2

    A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00219024, the US trial registry maintained by the National Library of Medicine. NCT00219024 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.